OUR COMPANY

The main activities of Nancyclotep

  • Research and development in radiochemistry / radiopharmacy
  • Support for preclinical research
  • Production of radiopharmaceuticals for clinical research
  • Support for academic and industrial clinical research
  • Support for healthcare activities (diagnosis and therapy) in Nuclear Medicine
Nancyclotep

Economic assessment of results and key contributions

PET

Over 230 scientific publications

PET

Over 130 clinical studies from phase 1 to 4 completed or ongoing

PET

Medical activity:
Over 70,000 PET-Scan examinations

Contributing to making Nancy the leading Nuclear Medicine department in France (4 PET-Scans, 5 gamma cameras, 14 rooms dedicated to Targeted Internal Radiotherapy)

Nancyclotep

Economic Report: Results - Investment - Growth

  • A positive result every year since its creation
  • 32 direct jobs created
  • Over €12M invested for the benefit of its 3 members
  • R&D laboratories in radiochemistry / radiopharmacy for UL
  • 3 PET-Scans and a clinical research team available to the CHRU